In the first three months of this year, the total amount of outbound licensing transactions of innovative drugs in our country exceeded 60 billion US dollars.

According to the National Medical Products Administration, in the first three months of this year, the total amount of overseas licensing transactions for innovative drugs in China exceeded 60 billion US dollars, close to half of the total for the year 2025; The latest statistics from the National Medical Products Administration show that as of March 27th, China has approved 10 innovative drugs for the year 2026, including 2 imports and 8 domestically produced ones. China has achieved a historic breakthrough in innovative drugs and maintained a good momentum and potential for development.